China NMPA Drug Inspection - Jinshaotang Chinese Herbal Pieces Co., Ltd. - Chinese herbal medicine slices

The Shandong Provincial Food and Drug Administration (Shandong FDA) issued an announcement on May 7, 2018, detailing significant quality deficiencies found in 72 batches of drugs. Inspections, conducted by 14 drug testing institutions, revealed two batches of finished drugs from two companies, including Hebei Kainuo Pharmaceutical Co., Ltd., and 70 batches of traditional Chinese medicine (TCM) slices from 47 companies, including Jinshaotang Traditional Chinese Medicine Slices Co., Ltd., to be substandard. The exact nature of these quality failures was not specified, but they represent a clear non-compliance with pharmaceutical quality standards. Operating within China's National Medical Products Administration (NMPA) regulatory framework, the Shandong FDA initiated stringent control measures. These actions included sealing, seizing, and suspending sales of the affected products, alongside mandatory recalls. Furthermore, legal proceedings have been launched against the responsible manufacturers and sampled units. The announcement emphasizes the need for intensified supervision by municipal food and drug administrations, urging companies to investigate the root causes of these issues, implement comprehensive rectification measures, and effectively eliminate potential public health risks.